A Randomized Controlled Trial of Pravastatin to Prevent Preeclampsia in High Risk Women

2024

Preeclampsia complicates approximately 3% to 5% of pregnancies and remains a major cause of maternal and neonatal morbidities and mortality. Women who experience preeclampsia in one pregnancy are at higher risk of developing preeclampsia in a subsequent pregnancy than those who have never experienced the condition. There is evidence from laboratory studies and clinical trials, as well as biological plausibility, to suggest that HMG-CoA reductase inhibitors (statins) may prevent the development of preeclampsia by reversing various pathophysiological pathways associated with preeclampsia. Pravastatin has a favorable safety profile and pharmacokinetic properties. The beneficial effects of pravastatin are likely to contribute substantially to preventing preeclampsia, and provide biological plausibility for its use in this setting. This protocol describes a double-blind randomized placebo-controlled trial of 1,550 high-risk women to assess whether daily treatment with pravastatin administered early in pregnancy reduces the rate of preeclampsia in high-risk women.

Other Direct/Model Services

Health-Related Activities

Professionals and Para-Professionals, General Public

Racial or Ethnic Minorities, Disadvantaged Circumstances, Limited English, Geographic Areas

National

N/A